For example, patients with breast cancer tumours overexpressing the HER2 receptor (in up to 30% of cases) showed favourable response to the FDA-approved anti-HER2 monoclonal antibody Trastuzumab [94,95,96]. Here, ERBB2 is linked to breast carcinoma.